心脏收缩性调节在患有缺血病源性心力衰竭的患者中的分子效应,通过转录组分析发现
E Lyasnikova1, K Sukhareva1,2, M Vander1
1Institute of Molecular Biology and Genetics, Almazov National Medical Research Centre, Saint Petersburg, Russia.
Frontiers in cardiovascular medicine
|February 16, 2024
概括
心脏收缩性调制 (CCM) 通过对响应者蛋白质稳定和线粒体健康的基因进行上调来改善心脏功能. 这表明CCM是CCM.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 关于心脏收缩性调制 (CCM) 的分子机制的数据有限.
- CCM涉及电刺激而不改变作用电位或机械激活.
- 了解CCM的分子效应对于优化治疗至关重要.
研究的目的:
- 调查12个月CCM治疗的临床,生理和转录效应.
- 为了确定CCM响应者和非响应者之间的分子差异.
- 阐明 CCM 疗效背后的基本分子机制.
主要方法:
- 在29名心力衰竭患者中进行了12个月的CCM治疗.
- 患者被划分为响应者 (n=13) 和不响应者 (n=16).
- 在CCM前后,对6名患者 (3名反应者,3名不反应者) 的心肌组织进行RNA测序 (RNA-seq) 分析.
主要成果:
- CCM反应者表现出显著的基因表达变化,主要是参与蛋白质稳定和线粒体功能的基因的上调.
- 响应者的基线心肌组织对线粒体矩阵,Z盘和与肌肉收缩相关的基因进行了丰富.
- 路径分析显示,CCM影响细胞呼吸,细胞亡和自信号传递.
结论:
- 十二个月的CCM疗法诱导了与细胞呼吸,细胞亡和自相关的信号通路中的分子变化.
- 心肌重塑后的CCM与收缩蛋白的基线表达,线粒体储备和低炎症标志物有关.
- CCM的有效性与响应者的独特分子形状有关,特别是在线粒体和蛋白质稳定路径方面.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:29Pathophysiology of Cardiac Performance
658
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
658